Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00098150
First received: December 3, 2004
Last updated: August 29, 2006
Last verified: August 2006
  Purpose

This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.


Condition Phase
Atopic Dermatitis
Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Atopic Dermatitis

Resource links provided by NLM:


Further study details as provided by Novartis:

Estimated Enrollment: 66
Study Start Date: July 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consenting patients who participated in the core clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00098150     History of Changes
Other Study ID Numbers: Ext 1 to ASM981C202
Study First Received: December 3, 2004
Last Updated: August 29, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Safety, atopic dermatitis, adverse event, SAE, extension

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Genetic Diseases, Inborn
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Skin Diseases
Skin Diseases, Eczematous
Skin Diseases, Genetic
Pimecrolimus
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Dermatologic Agents
Immunologic Factors
Immunosuppressive Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014